Ingevity Corporation

Ingevity is a mid-cap US specialty materials company in the late stages of a portfolio transformation. Through 2025–2026 it has divested its cyclical, tall-oil-based Industrial Specialties chemicals and its Road Markings coatings business, and it is running an advanced-stage sale process for its UK caprolactone polymers segment (Advanced Polymer Technologies, "Capa"). What remains, which management calls "New Ingevity", is two businesses. The first is Performance Materials, a globally dominant franchise in chemically activated wood-based carbon for automotive gasoline-vapour emissions canisters, earning EBITDA margins of about 53–55%. The second is Pavement Technologies, a technology-led asphalt-additives business (Evotherm warm-mix, emulsifiers, recycling additives, agrochemical dispersants) earning margins in the low-to-mid 20s. The equity case rests on a cash-generative, high-margin carbon franchise whose demand is being extended by the hybrid-vehicle mix shift. It is weighed against long-dated electrification risk, high customer concentration, leverage of about 2.5x, a near-zero book equity after impairments, and the November 2028 bond maturity.

Company's own description (FY2025 Annual Report / 10-K, paraphrased)

Ingevity describes itself as a global specialty materials company that develops advanced carbon and engineered material solutions. Its stated purpose is to improve mobility, strengthen and extend the life of infrastructure, and enhance industrial processes, under the tagline "Purify, Protect, Enhance". The 10-K adds that its products are largely renewably sourced. It lists applications including automotive gasoline vapour emissions control, food, water and chemical filtration, asphalt paving, agrochemical dispersants, bioplastics, coatings, elastomers and (until April 2026) road-marking paint. As of the FY2025 10-K it reported three segments: Performance Materials, Performance Chemicals and Advanced Polymer Technologies. In Q2 2026 Performance Chemicals was renamed Pavement Technologies, because Pavement Technologies became its only remaining product line after the two divestitures (Q2 2026 10-Q).

Business model and revenue model

Ingevity is almost entirely a product business. It manufactures and sells engineered materials and chemical additives under purchase orders and supply agreements. It has no material service, subscription or licensing revenue disclosed. Its economics differ sharply by segment:

Performance Materials (activated carbon): Revenue is driven by unit content per vehicle in evaporative-emissions canisters. The canister supplier is a Tier-1 customer such as PHINIA, A. Kayser, Korea Fuel-Tech or MAHLE. The vehicle OEM specifies the carbon to meet "life-of-vehicle" emissions standards (US Tier 3 / California LEV III, China 6). The business has long qualification cycles, high switching costs because of recall risk, and pricing power. About 65 automotive customers exist, and the ten largest account for about 90% of automotive sales (FY2025 10-K). A smaller filtration line (food, water, beverage, chemical purification) serves about 70 customers.

Pavement Technologies: Ingevity sells performance additives to asphalt producers and paving contractors. These include warm-mix additives (Evotherm), emulsifiers for pavement preservation, cold in-place recycling additives, and lignin-based agrochemical dispersants. It has about 600 customers in about 60 countries, and the ten largest account for about 38% of product-line sales (FY2025). Demand is seasonal (70–75% of revenue April–September) and ultimately funded by government infrastructure budgets.

• Advanced Polymer Technologies (held for strategic alternatives). Caprolactone monomer, polyols (Capa polyols for polyurethanes and coatings) and thermoplastics (Capa bioplastics) are made at a single plant in Warrington, UK. The segment has about 200 customers, with the top ten at about 44% of sales. The business is exposed to industrial and consumer cyclicality and to Asian competition.

Value-chain position

Ingevity sits in the mid-stream specialty conversion layer. In carbon, it converts hardwood sawdust and phosphoric acid into chemically activated carbon (granules, pellets, extruded honeycomb "scrubbers") at three US plants and two Chinese plants. Downstream it sells to Tier-1 fuel-system integrators. In pavement, it formulates surfactant and additive chemistries from purchased raw materials (maleic anhydride, ethoxylates, amines, tall oil fatty acid and lignin, now partly sourced externally after the CTO refinery sale) and sells to asphalt terminals and contractors. In APT, it converts cyclohexanone and hydrogen peroxide into caprolactone and derivatives.

Independent characterisation

Ingevity's investment identity has changed fundamentally since 2023. At spin-off it was a pine-chemicals company with a carbon business attached. The 2018 GP pine chemicals acquisition and the 2019 Capa acquisition pushed it toward a diversified specialty-chemicals profile. The 2023 collapse in Industrial Specialties volumes, the loss of economic CTO supply, and three years of impairments (about $307M of goodwill in FY2024, $184M APT goodwill and $109M Road Markings assets in FY2025, $32M APT assets in Q2 2026) exposed that most of the group's economic value sat in Performance Materials.

"New Ingevity" is effectively a niche industrial-materials franchise. Using FY2025 continuing segment EBITDA before corporate costs, about 78% of segment EBITDA came from automotive and filtration carbon ($326.3M of $418.7M). The remainder comes from an infrastructure-additives business. After the APT sale, Performance Materials would represent about 82–85% of segment EBITDA (analyst calculation from FY2025 segment data). The equity is therefore best analysed as a high-margin, slowly ex-growth ICE/hybrid content play with an infrastructure kicker. Valuation hinges on the duration of the gasoline-powertrain tail, especially hybrids, which require more sophisticated canister carbon. It does not hinge on chemicals-cycle dynamics.

Stated strategy (themes from the FY2025 10-K, 8 Dec 2025 Strategic Portfolio Update and 2026 earnings calls; paraphrased)

1. Simplify the portfolio into "New Ingevity". Two businesses, Performance Materials and Pavement Technologies, aligned around shared core competencies: highly engineered materials, deep technical expertise, leading positions and intellectual property. The intent is "best-in-class" EBITDA margins, consistency and superior cash generation.

2. Exit non-core and volatile lines. IS and CTO refinery sold (Jan 2026). Road Markings sold (Apr 2026). APT sale targeted by end-2026.

3. Execution excellence and cost discipline. The PC Repositioning delivered about $105M of cash savings since Nov 2023, plus about $12M lower depreciation and amortisation. About $20M of divestiture dis-synergies (stranded costs) were identified; about $10M was eliminated by Q2 2026, and the remainder is targeted by year-end. Full run-rate of savings is expected in 2027.

4. Deleveraging and capital return. Net leverage target of 2.0–2.5x. About $300M of share repurchases planned through 2027 (Q1 2026 call). $211M remains under the 2022 Authorization at 30 Jun 2026.

5. Organic growth in carbon and pavement. Capture the hybrid mix shift. Defend content in life-of-vehicle emissions systems. Grow Evotherm adoption, including Europe (BASt approval). Explore energy-storage carbons and renewable natural gas.

6. Pricing. Annual pricing actions in PM. Surcharges from April 2026 across businesses to offset raw-material and energy inflation linked to the Middle East conflict.

Management guidance / medium-term targets

Segment colour for 2026: PM full-year EBITDA margin in the "mid-50%" range, with H2 softer because of weaker North American auto production and planned maintenance outages at two plants. Pavement sales growth is mid-single-digit on a like-for-like basis. APT sales growth is low single digits, with Q2 helped by temporary competitor disruption. The outlook includes APT for the full year.

Ingevity does not publish list prices. Pricing is negotiated, typically through annual price actions in PM, with surcharges introduced in 2026. Launch years are given only where disclosed.

Source: S&P Global Market Intelligence standardised data (via StockAnalysis.com, updated 30 Jul 2026), reconciled where possible with FY2025 10-K, earnings releases and ARS. FY2023–FY2025 are continuing operations. FY2021–FY2022 are as originally reported, including IS. S&P "operating income" and "EBITDA" exclude special items (restructuring, impairments, litigation), so they approximate the company's adjusted measures, though methods differ.

Income statement

Discrepancy notes:

1. Company-reported FY2025 total net loss is $167.1M; continuing net loss is $150.3M, which includes $336.8M of pre-tax special charges (Q4 2025 release).

2. FY2025 total-company adjusted EBITDA was $397.5M including discontinued ops, versus $373.0M continuing.

3. FY2022 net income in some company references may differ slightly from S&P's $211.6M because of standardisation. Figures here follow S&P.

Margins and growth

Revenue CAGR: FY2021–FY2025 on the mixed reported basis is −4.3% a year (not like-for-like). FY2023–FY2025 on the continuing basis is −2.0% a year. The decline is driven by APT (−11.4% a year) and Performance Chemicals (−3.0% a year), with PM growing at +1.8% a year.

Balance sheet (year-end; S&P data)

Notes: FY2025 current liabilities include the BASF accrual ($95.4M including post-judgment interest), which was paid on 1 Apr 2026. At 30 Jun 2026 (Q2 10-Q via S&P): cash $97.4M; total debt incl. leases about $1,236M (current portion of LTD $144.0M; LTD $958.1M); equity $46.9M; total assets $1,538M. Company-reported net leverage was 2.6x at YE2025 and 2.5x at Q2 2026, down from 3.0x a year earlier.

Cash flow

2026 year to date (Q1–Q2 2026 releases and 10-Qs): Q2 operating cash flow was −$15.8M, including the $113.2M BASF payment. Q2 capex was about $10M. Divestiture proceeds were about $93M (IS, Q1) and $63.2M (Road Markings, Q2), which are not counted in free cash flow. Buybacks were about $52M in Q1 and $35M in Q2 (Q2 average cost $70.94 a share). TTM free cash flow to 30 Jun 2026 was $154.9M (S&P).

Ratios

Caveat: FY2023 working-capital days are distorted because year-end balances still included IS inventories while revenue is on the restated continuing basis. ROE and debt-to-equity are mathematically extreme because cumulative impairments and buybacks have reduced book equity to $29.7M. They are not meaningful indicators of operating performance.

Commentary: trends, inflections and drivers

Revenue. The reported series hides two different stories. Performance Materials has compounded steadily: $516.8M in FY2021 to $606.9M in FY2025, with a record $609.6M in FY2024 and TTM $622.2M at Q2 2026. Price, mix toward larger vehicles, and hybrid adoption more than offset flat global light-vehicle production. The chemicals side broke in 2023. Industrial Specialties volumes collapsed with destocking and the loss of competitive CTO feedstock, and APT has shrunk for three consecutive years ($244.7M FY2022 to $160.2M FY2025) because of industrial weakness, indirect tariff effects in 2025, and Asian caprolactone competition.

Margins. Gross margin rose from 34.2% (FY2022) to 39.5% (FY2025), and the TTM figure at Q2 2026 is 41.1%. This is a mix effect: lower-margin IS left the continuing base and the PM share rose. Company adjusted EBITDA margin from continuing ops reached 36.6% in Q2 2026 and about 35.5% in Q1 2026. That is consistent with management's "best-in-class margins" positioning for New Ingevity.

Earnings quality. GAAP earnings have been dominated by special items for three years. Cumulative goodwill and asset impairments total about $600M (FY2024 $306.6M continuing, FY2025 $293.1M, Q2 2026 $32.1M). Restructuring charges under the PC Repositioning Actions reached $353.7M through FY2025 (of which $248.3M non-cash), against an expected total of about $370M. The BASF matter cost $85.0M (FY2021), plus post-judgment interest and the $16.2M fee settlement in Q1 2026. Underlying adjusted EPS improved about 30% in FY2025 to $4.55, and 2026 guidance is $5.00–$5.45.

Cash. FY2025 free cash flow of $273.5M (23.4% margin) was an inflection. Capex fell to $57.7M from a $142.5M peak in FY2022, working capital was released (inventory down from $335M to $186M), and cash taxes were low. FY2026 free cash flow guidance of $220–245M excludes the $113.2M BASF payment.

Balance sheet. Gross debt fell from $1,535M (FY2023) to about $1,236M (Q2 2026). Book equity is minimal, so leverage must be judged on EBITDA and cash flow, not book ratios. Company-defined net leverage is 2.5x, and the stated target is 2.0–2.5x.

Management guidance (as of 29 Jul 2026)

FY2026: net sales $1.05–1.15B; adjusted EBITDA $380–400M (raised from $370–395M); adjusted EPS $5.00–5.45 (raised from $4.70–5.20); free cash flow $220–245M excluding the $113.2M BASF payment; net leverage target 2.0–2.5x. PM full-year EBITDA margin in the mid-50s, with H2 softer than H1. The outlook includes a full year of APT.

Consensus growth expectations

The forward P/E of about 13.2x at $72.41 implies consensus forward EPS of about $5.48 (analyst calculation from S&P data). This is near the top of the FY2026 guidance range, so the market expects continued EPS growth into FY2027, driven by buybacks, interest savings and residual cost-outs, rather than revenue growth. Reported revenue will step down again if APT (about $160–170M of annual sales) is sold.

Bull case

1. The hybrid cycle extends the carbon franchise. PM grew sales 4% and EBITDA 6% in Q2 2026 at a 53.6% margin. If North American hybrid adoption keeps displacing BEVs, PM can compound low-to-mid-single-digit EBITDA growth with minimal capex, supporting a higher multiple for a ~55%-margin niche monopoly-like asset.

2. Simplification plus deleveraging drives a re-rating. After the APT exit, "New Ingevity" would generate most of its EBITDA from a 50%+ margin segment and a mid-20s Pavement business. Net leverage moving from 2.5x toward 2.0x, with about $9% FCF yield on guidance, supports both buybacks and debt reduction. At about 9.3x 2026 EBITDA the stock does not price this mix shift.

3. Overhangs are cleared. The BASF litigation is closed after the $113.2M payment. Restructuring is substantially complete (about $10M of cash charges left), and the activist dispute is settled. GAAP and adjusted earnings should converge from 2027, improving earnings quality.

Bear case

1. Terminal-value risk. About 78% of segment EBITDA (FY2025) depends on gasoline-powertrain vehicles. Any reacceleration in BEV adoption, especially in China (about 20% of PM sales by the company's own split), permanently erodes volumes. Customer concentration (top ten auto customers about 90%) amplifies the downside.

2. Capital-allocation track record. Capa (≈$652.5M) and Ozark (≈$325M) produced large impairments and below-cost exits; Road Markings sold for about $65M. The APT sale is likely below book, given the $32.1M Q2 2026 impairment. Investors may discount future M&A or growth bets, such as energy-storage carbons.

3. Shrinking base and refinancing. Revenue falls toward about $0.95–1.0B after APT. The $550M 2028 notes must be refinanced in a higher-rate world than their 3.875% coupon, raising interest cost. Book equity of about $47M leaves no balance-sheet cushion against further write-downs.

Analyst verdict

Ingevity in October 2026 is a materially better business than the company that entered 2024, but it is also a smaller and more concentrated one. Management under David Li has executed the hard parts of the plan quickly. It exited Industrial Specialties and the CTO refinery on 1 January 2026, sold Road Markings to PPG in April, closed the eight-year BASF dispute with a $113.2M payment, extended the revolver to 2031, and lifted company adjusted EBITDA margins into the mid-30s (36.6% in Q2 2026). Performance Materials is the crown jewel. A 53–55% EBITDA margin, an entrenched qualification position with global Tier-1 canister makers, and a demand boost from the consumer shift toward hybrids make it one of the most profitable niches in specialty materials.

The valuation tension is about duration, not quality. At about 9.3x 2026 guided EBITDA and about 14x adjusted EPS, with roughly a 9% free-cash-flow yield, the market is effectively capitalising PM as a slowly melting asset. That is a defensible stance given BEV risk, roughly 90% automotive customer concentration and a history of value-destructive diversification (Capa, Ozark). The near-term equity story is mechanical and fairly visible: buybacks (about $300M planned through 2027), deleveraging toward 2.0x, interest savings, residual dis-synergy removal, and an APT exit that should improve mix even if it crystallises a loss.

Our synthesis is constructive but valuation-capped. Upside requires evidence that the hybrid tailwind is durable and that capital will be returned rather than redeployed into speculative adjacencies such as battery carbons. Downside is limited in the near term by strong cash generation and closed litigation, but it rises sharply if auto production weakens or refinancing costs jump before 2028. The key tests over the next twelve months are the APT sale price, PM margin delivery through a softer H2 2026, and the plan for the 2028 notes. On balance, Ingevity screens as a cash-yield and execution story deserving a neutral-to-modestly-positive stance, consistent with the prevailing Hold consensus.

SOURCES (primary first)

• Ingevity Corporation, Form 10-K for FY2025 (filed 26 Feb 2026), SEC EDGAR: sec.gov/Archives/edgar/data/1653477/000165347726000014/ngvt-20251231.htm

• Ingevity Corporation, 2025 Annual Report (ARS), SEC EDGAR

• Ingevity Corporation, 2026 Proxy Statement (DEF 14A, filed 17 Mar 2026), SEC EDGAR

• Ingevity Corporation, Form 10-Q Q1 2026 (period ended 31 Mar 2026) and Form 10-Q Q2 2026 (period ended 30 Jun 2026), SEC EDGAR

• Ingevity 8-Ks: 8 Dec 2025 (portfolio review; leadership transitions), 5 Jan 2026 (IS sale completion), 29 Apr 2026 (AGM results), 29 Jul 2026 (Q2 2026 results, Exhibit 99.1)

• Ingevity press releases via Business Wire: FY2025 results (25 Feb 2026); Q1 2026 results (6 May 2026); Q2 2026 results (29 Jul 2026); Ozark Materials sale to PPG (15 Apr 2026); David H. Li appointment (10 Mar 2025); Jefferies conference (3 Sep 2026); Ultrapolymers partnership (9 Jul 2024); 2023 Sustainability Report (13 Jun 2024)

• Prior Ingevity 10-Ks (FY2021, FY2022, FY2023, FY2024) and 2020–2021 8-Ks for debt and history

• Earnings-call coverage: Q4 2025, Q1 2026 and Q2 2026 transcripts and summaries (Insider Monkey, MarketBeat, Motley Fool via Webull)

• S&P Global Market Intelligence standardised financials via StockAnalysis.com (income statement, balance sheet, cash flow, ratios; data updated 30 Jul 2026; prices to 2 Oct 2026)

• Ownership: Simply Wall St; Yahoo Finance; Equibles; Blarkad (13F aggregators)

• Analyst data: Fintel; Zacks (1 Jan 2026 report)

• Transaction coverage: Lubes'n'Greases (Mainstream deal); Perstorp / Chemical Engineering / PCI (Capa acquisition); VectorShift (PPG–Ozark)

• Peer benchmark: Arkema Full-Year 2025 Results (Business Wire, 25 Feb 2026)

• Governance: Wachtell Lipton (Vision One cooperation agreement); Justia contract filings (cooperation agreement; CEO offer letter)

These include the auditor's FY2025 confirmation, the full board roster, credit ratings, MSCI, Sustainalytics and CDP scores, third-party market sizes, the 2018 GP and 2022 Ozark acquisition values, the identity of strategic-investment counterparties, the leader of Pavement Technologies after Rich White's transition, and the disposition of specific Performance Chemicals plants. They should be checked before any investment or credit decision.

--